Here’s Why Amgen, Inc. (AMGN) May Rise In Today’s Trading

March 2, 2015 11:23 AM

15 0

Amgen, Inc. (NASDAQ:AMGN) announced before the US markets opened for trading on Monday that its cancer therapy drug Kyprolis performed better than rival treatment Velcade in treating relapsed multiple myeloma, which is the second most common form of blood cancer.

The California-based biotech said that patients in the trial taking Kyprolis after the second onset of multiple myeloma lived 18.7 months without their condition worsening, which was about twice the length of time for those taking Velcade. Furthermore, Kyprolis patients also reported fewer cases of ...

Read more

To category page